{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T21:12:06Z","timestamp":1742937126464,"version":"3.40.3"},"reference-count":464,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323776844"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/b978-0-323-77684-4.00014-3","type":"book-chapter","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T12:30:05Z","timestamp":1665145805000},"page":"125-174.e30","source":"Crossref","is-referenced-by-count":0,"title":["Adenocarcinoma of the uterine corpus and sarcomas of the uterus"],"prefix":"10.1016","author":[{"given":"Ramez Nassef","family":"Eskander","sequence":"first","affiliation":[]},{"given":"David S.","family":"Miller","sequence":"additional","affiliation":[]},{"given":"Matthew","family":"Powell","sequence":"additional","affiliation":[]},{"given":"William T.","family":"Creasman","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"year":"2016","series-title":"Cancer Facts and Figs","key":"10.1016\/B978-0-323-77684-4.00014-3_bib0010"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM197901043000103","article-title":"Endometrial cancer and estrogen use (report of a large case-control study)","volume":"300","author":"Antunes","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0020","first-page":"129","article-title":"The effects of tamoxifen on the endometrium","volume":"9","author":"Barakat","year":"1995","journal-title":"Oncology (Huntingt)"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1006\/gyno.1994.1271","article-title":"Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histological features","volume":"55","author":"Barakat","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0030","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0140-6736(96)07365-5","article-title":"Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women","volume":"349","author":"Beresford","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0035","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0040","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0002-9378(11)91709-8","article-title":"Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study","volume":"167","author":"Brinton","year":"1992","journal-title":"J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0045","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","article-title":"American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0050","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/S0020-7292(06)60031-3","article-title":"Carcinoma of the corpus uteri","volume":"95","author":"Creasman","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0055","doi-asserted-by":"crossref","first-page":"80.e1","DOI":"10.1016\/j.ajog.2008.07.062","article-title":"A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial","volume":"200","author":"Duffy","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0060","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0065","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/jnci\/59.4.1055","article-title":"Epidemiology of endometrial cancer","volume":"59","author":"Elwood","year":"1977","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0070","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0029-7844(97)00668-6","article-title":"Profiles of women 45 years of age and younger with endometrial cancer","volume":"91","author":"Evans-Metcalf","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0075","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14","volume":"86","author":"Fisher","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0080","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0085","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1055-9965.EPI-07-2686","article-title":"A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer","volume":"17","author":"Gunter","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0090","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0140-6736(76)92099-7","article-title":"Cancer of the uterine corpus after hormonal treatment for breast cancer","volume":"1","author":"Hoover","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0095","first-page":"357","article-title":"Endometrial carcinoma in women 65 years of age or older: a clinicopathologic study","volume":"17","author":"Kaku","year":"1996","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0100","first-page":"273","article-title":"Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens","volume":"69","author":"Killackey","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0105","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/1097-0142(19870501)59:9<1665::AID-CNCR2820590924>3.0.CO;2-2","article-title":"Smoking, body weight, and early stage endometrial cancer","volume":"59","author":"Lawrence","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0110","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1002\/1097-0142(19930601)71:11<3575::AID-CNCR2820711119>3.0.CO;2-0","article-title":"Dietary factors and the risk of endometrial cancer","volume":"71","author":"Levi","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0115","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/01.AOG.0000154885.44002.ae","article-title":"Gynecologic cancer as a \u201csentinel cancer\u201d for women with hereditary nonpolyposis colorectal cancer syndrome","volume":"105","author":"Lu","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0120","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0090-8258(74)90003-1","article-title":"Risk factors for endometrial cancer","volume":"2","author":"MacMahon","year":"1974","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0125","first-page":"S1","article-title":"Overview of studies on endometrial cancer and other types of cancer in humans: perspective of an epidemiologist","volume":"24","author":"MacMahon","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0130","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1993.11.3.485","article-title":"High grade endometrial carcinoma in tamoxifen treated breast cancer patients","volume":"11","author":"Magriples","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0135","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(05)66455-0","article-title":"Endometrial cancer and hormone replacement therapy in the Million Women Study","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0140","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S0002-9378(36)90035-2","article-title":"Relationship of endometrial hyperplasia to adenocarcinoma of the endometrium","volume":"32","author":"Novak","year":"1936","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0145","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1006\/gyno.1993.1112","article-title":"Endometrial cancer in postmenopausal women with and without previous estrogen replacement treatment: comparison of clinical and histopathological characteristics","volume":"49","author":"Nyholm","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0150","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1001\/jama.1991.03470130088034","article-title":"Upper-body fat distribution and endometrial cancer risk","volume":"266","author":"Schapira","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0155","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMoa052627","article-title":"Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome","volume":"354","author":"Schmeler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0160","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJM197512042932302","article-title":"Association of exogenous estrogen and endometrial carcinoma","volume":"293","author":"Smith","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0165","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0170","first-page":"321","article-title":"Relationship of endometrial cancer risk to past and contemporary body size and body fat distribution","volume":"2","author":"Swanson","year":"1993","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0175","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djh034","article-title":"Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability","volume":"96","author":"Umar","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0180","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(98)04394-3","article-title":"Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women","volume":"352","author":"Veronesi","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0185","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/jnci\/91.13.1131","article-title":"Risk of endometrial cancer following estrogen replacement with and without progestins","volume":"91","author":"Weiderpass","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0190","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2009.07.016","article-title":"The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes","volume":"115","author":"Abu-Rustum","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0195","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0090-8258(92)90296-U","article-title":"Identification of patients with stage I uterine endometrial adenocarcinoma at high risk of recurrence by DNA ploidy myometrial invasion and vascular invasion","volume":"45","author":"Ambros","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0200","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/AOG.0b013e3181b48feb","article-title":"The role of transvaginal ultrasonography in the evaluation of postmenopausal bleeding. ACOG Committee Opinion No. 440","volume":"114","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0205","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/01.AOG.0000450757.18294.cf","article-title":"ACOG Committee Opinion No. 601: tamoxifen and uterine cancer","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0210","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/01.AOG.0000462977.61229.de","article-title":"Endometrial cancer. ACOG Practice Bulletin No. 149","volume":"125","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0215","first-page":"306","article-title":"Correlation between clinical and histopathologic risk factors; i.e., lymph node metastasis in early endometrial cancer","volume":"4","author":"Ayhan","year":"1994","journal-title":"Int J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0220","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1525-1438.1995.05020112.x","article-title":"Confirmation of the prognostic value of the ECPI-1 score in FIGO stage I endometrial cancer patients with long follow up","volume":"5","author":"Baak","year":"1995","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0225","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ygyno.2012.06.018","article-title":"Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement","volume":"127","author":"Boren","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0230","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2009.06.011","article-title":"Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review","volume":"115","author":"Boruta","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0235","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0090-8258(90)90287-U","article-title":"Detection of endometrial cancer by transvaginal ultrasonography with color flow imaging and blood flow analysis","volume":"40","author":"Bourne","year":"1991","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0240","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/ijgc-00009577-200309000-00015","article-title":"FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival","volume":"13","author":"Bristow","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0245","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0025-6196(12)65126-X","article-title":"DNA ploidy in endometrial carcinoma: major objective prognostic factor","volume":"65","author":"Britton","year":"1990","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_bib0250","first-page":"CD007585","article-title":"Lymphadenectomy for the management of endometrial cancer","author":"Bryant","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0255","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0002-9378(89)90105-1","article-title":"Preoperative sonographic evaluation of endometrial cancer","volume":"160","author":"Cacciatore","year":"1989","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0260","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/0090-8258(92)90130-B","article-title":"Uterine papillary serous carcinoma","volume":"47","author":"Carcangiu","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0265","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0090-8258(03)00195-1","article-title":"Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium","volume":"90","author":"Chan","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0270","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004347-198512000-00001","article-title":"Endometrial papillary carcinoma: two clinical pathological types","volume":"4","author":"Chen","year":"1985","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0275","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1471-0528.2006.00914.x","article-title":"Investigating postmenopausal bleeding for endometrial cancer: cost-effectiveness of initial diagnostic strategies","volume":"113","author":"Clark","year":"2006","journal-title":"BJOG"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0280","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.288.13.1610","article-title":"Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia a systematic quantitative review","volume":"288","author":"Clark","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0285","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1006\/gyno.2002.6825","article-title":"Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer?","volume":"87","author":"Cohn","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0290","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1006\/gyno.1993.1157","article-title":"DNA flow cytometric analysis of clinical stage I endometrial carcinomas with lymph node metastases","volume":"50","author":"Coleman","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0295","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1006\/gyno.1999.5415","article-title":"Significance of adnexal involvement in endometrial carcinoma","volume":"74","author":"Connell","year":"1999","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/B978-0-323-77684-4.00014-3_bib0300","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijgo.2009.02.010","article-title":"Revised FIGO staging for carcinoma of the endometrium","volume":"105","author":"Creasman","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_bib0305","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0002-9378(99)70431-X","article-title":"Significance of true surgical pathologic staging: a Gynecologic Oncology Group study","volume":"181","author":"Creasman","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0310","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0002-9378(16)32684-9","article-title":"Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals","volume":"141","author":"Creasman","year":"1981","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0315","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ygyno.2004.08.019","article-title":"Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium","volume":"95","author":"Creasman","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0320","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00006250-198003000-00019","article-title":"Clinical correlation of estrogen, progesterone binding proteins in human endometrial adenocarcinoma","volume":"55","author":"Creasman","year":"1980","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0325","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8","article-title":"Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study","volume":"60","author":"Creasman","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0330","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/0002-9378(71)90571-0","article-title":"The prognostic value of peritoneal cytology in gynecologic malignant disease","volume":"110","author":"Creasman","year":"1971","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0335","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/0002-9378(85)90671-4","article-title":"Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma","volume":"151","author":"Creasman","year":"1985","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0340","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/gyno.1998.5098","article-title":"Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma","volume":"70","author":"Dasarahally","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0345","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/1097-0142(20001015)89:8<1765::AID-CNCR17>3.0.CO;2-F","article-title":"The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis","volume":"89","author":"Dijkhuizen","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0350","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/0002-9378(85)90371-0","article-title":"Risk factors in recurrent patterns in stage I endometrial carcinoma","volume":"151","author":"DiSaia","year":"1985","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0355","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1067\/mob.2000.106251","article-title":"Preoperative CA125 in endometrial cancer. Is it useful?","volume":"182","author":"Dotters","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0360","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1006\/gyno.1999.5454","article-title":"Survival of women with surgical stage II endometrial cancer","volume":"74","author":"Eltabbakh","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0365","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1006\/gyno.1995.1066","article-title":"Predicting endometrial cancer among older women who present with abnormal vaginal bleeding","volume":"56","author":"Feldman","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0370","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/1097-0142(20011115)92:10<2569::AID-CNCR1609>3.0.CO;2-3","article-title":"The angiogenic \u201cvascular endothelial growth factor\/flk-1(KDR) receptor\u201d pathway in patients with endometrial carcinoma prognostic and therapeutic implications","volume":"92","author":"Giatromanolaki","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0375","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0020-7292(96)02720-8","article-title":"Transvaginal ultrasound, uterine biopsy and hysteroscopy for postmenopausal bleeding","volume":"55","author":"Giusa-Chiferi","year":"1996","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0380","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1006\/gyno.1994.1208","article-title":"Uterine papillary serous carcinoma: patterns of metastatic spread","volume":"54","author":"Goff","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0385","first-page":"727","article-title":"The accuracy of endometrial Pipelle sampling with or without sonographic measurement of endometrial thickness","volume":"82","author":"Goldchmit","year":"1993","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0390","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0002-9378(94)70209-8","article-title":"Unusual ultrasound appearance of the uterus in patients receiving tamoxifen","volume":"170","author":"Goldstein","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0395","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0090-8258(89)90136-4","article-title":"Preoperative assessment of myometrial invasion of endometrial adenocarcinoma by ultrasound and MRI","volume":"34","author":"Gordon","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0400","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9378(91)90622-X","article-title":"Endometrial thickness as measured by endovaginal ultrasound for identifying endometrial abnormality","volume":"164","author":"Granberg","year":"1991","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0405","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1006\/gyno.1998.4956","article-title":"Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients","volume":"69","author":"Grice","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0410","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0090-8258(90)90116-3","article-title":"Prognostic value of peritoneal cytology in endometrial carcinoma","volume":"36","author":"Grimshaw","year":"1990","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0415","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/1097-0142(19850415)55:8<1753::AID-CNCR2820550823>3.0.CO;2-P","article-title":"Prognostic significance of lymph-vascular space invasion in stage I endometrial cancer","volume":"55","author":"Hanson","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0420","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ygyno.2007.01.041","article-title":"Outcomes in surgical stage I uterine papillary serous carcinoma","volume":"105","author":"Havrilesky","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0425","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ygyno.2005.07.014","article-title":"Resection of lymph node metastases influences survival in Stage III endometrial cancer","volume":"99","author":"Havrilesky","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0430","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ygyno.2006.08.027","article-title":"The prognostic significance of positive peritoneal cytology and adnexal\/serosal metastasis in stage IIIA endometrial cancer","volume":"104","author":"Havrilesky","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0435","doi-asserted-by":"crossref","first-page":"9038","DOI":"10.1158\/0008-5472.CAN-09-1499","article-title":"Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer","volume":"69","author":"Huang","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0440","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2010.02.006","article-title":"Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas","volume":"117","author":"Huang","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0445","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ygyno.2003.08.027","article-title":"Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy","volume":"91","author":"Huh","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0450","first-page":"983","article-title":"Prognostic factors in surgical stage III and IV carcinoma of the endometrium","volume":"84","author":"Kadar","year":"1994","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0455","first-page":"655","article-title":"Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus","volume":"80","author":"Kadar","year":"1992","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0460","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3109\/02841868909092271","article-title":"Oestrogen and progestin receptors as prognostic indicators in endometrial cancer","volume":"28","author":"Kauppila","year":"1989","journal-title":"Acta Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0465","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/gyno.1995.1005","article-title":"Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling","volume":"56","author":"Kilgore","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0470","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0360-3016(88)90050-8","article-title":"Absence of prognostic significance, peritoneal dissemination and treatment advantage in endometrial cancer patients with positive peritoneal cytology","volume":"4","author":"Konski","year":"1988","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0475","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ygyno.2007.09.031","article-title":"Society of Gynecologic Oncologists Education Committee. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions","volume":"107","author":"Lancaster","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0480","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJM199712183372502","article-title":"Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease","volume":"337","author":"Langer","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0485","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ygyno.2008.12.017","article-title":"Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma","volume":"113","author":"Leitao","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0490","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0090-8258(92)90224-7","article-title":"Uterine papillary serous carcinoma treated with PAC","volume":"46","author":"Levenback","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0495","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1046\/j.1525-1438.1996.06060473.x","article-title":"The prognostic significance of positive peritoneal cytology in endometrial cancer","volume":"6","author":"Lo","year":"1996","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0500","first-page":"63","article-title":"Prognostic factors associated with recurrence in clinical stage I adenocarcinoma","volume":"78","author":"Lurain","year":"1991","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0505","first-page":"175","article-title":"Prognostic significance of positive peritoneal cytology in clinical stage I adenocarcinoma of the endometrium","volume":"74","author":"Lurain","year":"1989","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0510","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0090-8258(78)90008-2","article-title":"Endometrial carcinoma: a new method of classification of therapeutic and prognostic significance","volume":"6","author":"Lutz","year":"1978","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0515","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2008.01.023","article-title":"Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging","volume":"109","author":"Mariani","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0520","article-title":"Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer","volume":"348","author":"Mariani","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0525","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1067\/mob.2000.107335","article-title":"Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?","volume":"182","author":"Mariani","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0530","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1006\/gyno.2002.6789","article-title":"Stage IIIC endometrioid corpus cancer includes distinct subgroups","volume":"87","author":"Mariani","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0535","first-page":"3741","article-title":"Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN","volume":"61","author":"Matsushima-Nishiu","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0540","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1006\/gyno.1997.4617","article-title":"Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women","volume":"65","author":"Matthews","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0545","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1006\/gyno.2001.6157","article-title":"Analysis of FIGO Stage IIIc endometrial cancer patients","volume":"81","author":"McMeekin","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0550","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1525-1438.1992.02050225.x","article-title":"Clinical significance of malignant peritoneal cytology in stage I endometrial carcinoma","volume":"2","author":"Milosevic","year":"1992","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0555","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0090-8258(90)90166-I","article-title":"Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group study","volume":"36","author":"Morrow","year":"1990","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0560","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0090-8258(91)90086-K","article-title":"Relationship between surgical pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium","volume":"40","author":"Morrow","year":"1991","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0565","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/jnci\/92.11.924","article-title":"Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers","volume":"92","author":"Mutter","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0570","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ygyno.2009.07.030","article-title":"An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)","volume":"115","author":"Nickles Fader","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0575","first-page":"899","article-title":"Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression","volume":"16","author":"Nordstr\u00f6m","year":"1996","journal-title":"Anticancer Res"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0580","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/bjc.1997.313","article-title":"Treatment of node positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy","volume":"75","author":"Onda","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0585","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0090-8258(82)90011-7","article-title":"Endometrial carcinoma with cervical involvement (stage II): prognostic factors in value of combined radiological surgical treatment","volume":"13","author":"Onsrud","year":"1982","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0590","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/jnci\/djn397","article-title":"Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial","volume":"100","author":"Panici","year":"2008","journal-title":"JNCI"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0595","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1006\/gyno.1995.1202","article-title":"Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma","volume":"58","author":"Pfisterer","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0600","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0029-7844(95)00037-R","article-title":"HER-2\/neu, p53, and DNA analysis as prognosticators for survival in endometrial carcinoma","volume":"85","author":"Pisani","year":"1995","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0605","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1006\/gyno.1998.5150","article-title":"Staging and therapeutic value of lymphadenectomy in endometrial cancer","volume":"70","author":"Podratz","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0610","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/0002-9378(93)90370-X","article-title":"DNA analysis facilitates the pretreatment identification of high-risk endometrial cancer patients","volume":"168","author":"Podratz","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0615","series-title":"Steroids and Endometrial Cancer","first-page":"101","article-title":"Estrogen progesterone receptors in endometrial carcinoma","author":"Pollow","year":"1989"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0620","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/0090-8258(85)90269-0","article-title":"Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate","volume":"21","author":"Quinn","year":"1985","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0625","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1006\/gyno.1993.1006","article-title":"A new aggressive treatment approach to high grade endometrial cancer of possible benefit to patients with stage I uterine papillary cancer","volume":"48","author":"Rosenberg","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0630","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0090-8258(74)90024-9","article-title":"The role of radical hysterectomy in adenocarcinoma of the endometrium","volume":"2","author":"Rutledge","year":"1974","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0635","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ygyno.2006.03.003","article-title":"Is peritoneal cytology a prognostic factor of endometrial cancer confined to the uterus?","volume":"103","author":"Saga","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0640","first-page":"216","article-title":"Tumor size in endometrial cancer: a prospective factor for lymph node metastases","volume":"70","author":"Schink","year":"1987","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0645","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/AOG.0b013e3181aa96c7","article-title":"Comprehensive surgical staging for endometrial cancer in obese patients: comparing robotics and laparotomy","volume":"114","author":"Seamon","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0650","first-page":"963","article-title":"Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas","volume":"10","author":"Sherman","year":"1997","journal-title":"Mod Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0655","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3322\/caac.20063","article-title":"Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening","volume":"60","author":"Smith","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0660","doi-asserted-by":"crossref","first-page":"202.e1","DOI":"10.1016\/j.ajog.2007.04.046","article-title":"The role of vaginal hysterectomy in the treatment of endometrial cancer","volume":"197","author":"Smith","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0665","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1001\/jama.280.17.1510","article-title":"Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities","volume":"280","author":"Smith-Bindman","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0670","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0002-9378(85)90112-7","article-title":"Intraperitoneal chromic phosphate P-32 suspension therapy in malignant peritoneal cytology and endometrial carcinoma","volume":"153","author":"Soper","year":"1985","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0675","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1525-1438.1994.04020094.x","article-title":"Nuclear morphometry and DNA flow cytometry as prognostic methods for endometrial carcinoma","volume":"4","author":"Sorbe","year":"1994","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0680","first-page":"954","article-title":"Pipelle endometrial sampling in patients with known endometrial carcinoma","volume":"77","author":"Stovall","year":"1991","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0685","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0002-9378(94)70222-5","article-title":"Prognostic value of flow cytometric deoxyribonucleic acid in endometrial carcinoma: comparison with other clinical-pathologic parameters","volume":"170","author":"Susini","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0690","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/gyno.1998.5086","article-title":"Ovarian metastasis in endometrial carcinoma","volume":"70","author":"Takeshima","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0695","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1471-0528.1993.tb15239.x","article-title":"Flow cytometric studies of ploidy and proliferative indices in the Yorkshire trial of adjuvant progestogen treatment of endometrial cancer","volume":"100","author":"Thornton","year":"1993","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0700","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0140-6736(09)62002-X","article-title":"Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis","volume":"375","author":"Todo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0705","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1006\/gyno.1998.5254","article-title":"Lymph node sampling and survival in endometrial cancer","volume":"71","author":"Trimble","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0710","first-page":"775","article-title":"The prognostic significance of peritoneal cytology for stage I endometrial cancer","volume":"74","author":"Turner","year":"1989","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0715","first-page":"195","article-title":"Transvaginal sonography of the endometrium in postmenopausal women","volume":"78","author":"Varner","year":"1991","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0720","doi-asserted-by":"crossref","first-page":"679.e1","DOI":"10.1016\/j.ajog.2008.03.032","article-title":"Robotic surgery in gynecologic oncology: program initiation and outcomes after the first year with comparison with laparotomy for endometrial cancer staging","volume":"198","author":"Veljovich","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0725","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.1200\/JCO.2009.22.3248","article-title":"Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: gynecologic Oncology Group Study LAP2","volume":"27","author":"Walker","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/B978-0-323-77684-4.00014-3_bib0730","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1200\/JCO.2011.38.8645","article-title":"Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2","volume":"30","author":"Walker","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_bib0735","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ygyno.2005.09.042","article-title":"Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers","volume":"101","author":"Wang","year":"2006","journal-title":"Gynecol Oncol Apr"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0740","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0002-9378(97)70295-3","article-title":"Vaginal ultrasonography versus endometrial biopsy in women with postmenopausal bleeding","volume":"177","author":"Weber","year":"1997","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0745","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2009.06.019","article-title":"Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: unraveling a mystery","volume":"115","author":"Wethington","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0750","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00006250-198309000-00019","article-title":"Malignant peritoneal cytology as prognostic indicator in stage I endometrial cancer","volume":"62","author":"Yazigi","year":"1983","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0755","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/1097-0142(19920115)69:2<488::AID-CNCR2820690236>3.0.CO;2-O","article-title":"Endometrial adenocarcinoma with squamous cell differentiation","volume":"69","author":"Abeler","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0760","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/ajcp\/77.6.655","article-title":"Carcinoma of the endometrium. IV: mixed adenosquamous carcinoma","volume":"77","author":"Alberhasky","year":"1982","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0765","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/1097-0142(19930915)72:6<1959::AID-CNCR2820720628>3.0.CO;2-P","article-title":"Malignant lymphoma of the uterus","volume":"72","author":"Aozasa","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0770","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.1525-1438.1998.09817.x","article-title":"Anatomical and pathological study of retroperitoneal nodes in endometrial cancer","volume":"8","author":"Benedetti-Panici","year":"1998","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0775","first-page":"109","article-title":"Uterine papillary serous carcinoma","volume":"69","author":"Chambers","year":"1987","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0780","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004347-198512000-00001","article-title":"Endometrial papillary carcinoma: two clinical pathological types","volume":"4","author":"Chen","year":"1985","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0785","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/1097-0142(19820415)49:8<1511::AID-CNCR2820490802>3.0.CO;2-6","article-title":"Carcinoma of the endometrium. I: a clinicopathological study of clear cell carcinoma and secretory carcinoma","volume":"49","author":"Christopherson","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0790","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/ajcp\/77.5.534","article-title":"Carcinoma of the endometrium. II: papillary adenocarcinoma: a clinico-pathological study of 46 patients","volume":"77","author":"Christopherson","year":"1982","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0795","first-page":"569","article-title":"Carcinoma of the endometrium. III: analysis of 865 cases of adenocarcinoma and adenocanthoma","volume":"59","author":"Connely","year":"1982","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0800","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/1097-0142(19820701)50:1<163::AID-CNCR2820500131>3.0.CO;2-K","article-title":"Simultaneous presentation of carcinoma involving the ovary and uterine corpus","volume":"50","author":"Eifel","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0805","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/1097-0142(19950501)75:9<2239::AID-CNCR2820750908>3.0.CO;2-7","article-title":"Uterine papillary serous carcinoma","volume":"75","author":"Gitsch","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0810","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1006\/gyno.1994.1208","article-title":"Uterine papillary serous carcinoma: patterns of metastatic spread","volume":"54","author":"Goff","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0815","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1006\/gyno.1994.1207","article-title":"Uterine papillary serous carcinoma revisited","volume":"54","author":"Hendrickson","year":"1991","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0820","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0090-8258(82)90076-2","article-title":"Adenocarcinoma of the endometrium: analysis of 256 cases of carcinoma limited to the uterine corpus","volume":"13","author":"Hendrickson","year":"1982","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0825","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/00006250-198605000-00013","article-title":"Papillary serous adenocarcinomas of the endometrium","volume":"67","author":"Jeffrey","year":"1986","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0830","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1006\/gyno.1996.0005","article-title":"Endometrial carcinoma associated with hyperplasia","volume":"60","author":"Kaku","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0835","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0840","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1525-1438.1997.00412.x","article-title":"Advanced endometrial adenocarcinoma following endometrial ablation: a case report and review of the literature","volume":"7","author":"Klein","year":"1997","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0845","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/1097-0142(197602)37:2<872::AID-CNCR2820370236>3.0.CO;2-L","article-title":"Clear cell carcinoma of the endometrium: analysis of 21 cases","volume":"37","author":"Kurman","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0850","first-page":"437","article-title":"Incidence and prognosis of endometrial carcinoma by histologic grade and extent","volume":"35","author":"Ng","year":"1970","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0855","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/ajcp\/59.6.765","article-title":"Mixed adenosquamous carcinoma of the endometrium","volume":"59","author":"Ng","year":"1973","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0860","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/1097-0142(19920115)69:2<496::AID-CNCR2820690237>3.0.CO;2-Q","article-title":"Uterine papillary serous carcinoma after radiation therapy for carcinoma of the cervix","volume":"69","author":"Parkash","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0865","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/1097-0142(197904)43:4<1448::AID-CNCR2820430435>3.0.CO;2-9","article-title":"Clear cell carcinoma of the endometrium","volume":"43","author":"Photopulos","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0870","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/1097-0142(197707)40:1<119::AID-CNCR2820400121>3.0.CO;2-9","article-title":"Adenosquamous carcinoma of the endometrium","volume":"40","author":"Salazar","year":"1977","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0875","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0090-8258(85)90005-8","article-title":"Second primary malignancy in endometrial carcinoma patients","volume":"22","author":"Schwartz","year":"1985","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0880","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/1097-0142(197211)30:5<1307::AID-CNCR2820300524>3.0.CO;2-R","article-title":"Adenoacanthoma and mixed adenosquamous carcinoma of the endometrium","volume":"30","author":"Silverberg","year":"1972","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0885","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/1097-0142(197305)31:5<1127::AID-CNCR2820310514>3.0.CO;2-E","article-title":"Clear cell carcinoma of the endometrium: clinical-pathological and ultra-structural findings","volume":"31","author":"Silverberg","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0890","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1525-1438.1998.09806.x","article-title":"Endometrial carcinoma: two or three entities?","volume":"8","author":"Sivridis","year":"1998","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0895","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00004347-199404000-00004","article-title":"Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors","volume":"13","author":"Umpierre","year":"1994","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0900","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/1097-0142(19911115)68:10<2293::AID-CNCR2820681032>3.0.CO;2-V","article-title":"The significance of squamous differentiation","volume":"68","author":"Zaino","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0905","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0090-8258(84)90200-2","article-title":"Synchronous carcinomas of the uterine corpus and ovary","volume":"19","author":"Zaino","year":"1984","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/B978-0-323-77684-4.00014-3_bib0910","first-page":"419","article-title":"Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients","volume":"56","author":"Aalders","year":"1980","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0915","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0920","first-page":"461","article-title":"Clinical results and histological changes following irradiation treatment of cancer of the corpus uteri","volume":"36","author":"Arneson","year":"1936","journal-title":"AJR"},{"issue":"9658","key":"10.1016\/B978-0-323-77684-4.00014-3_bib0925","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(08)61767-5","article-title":"Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRCASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis","volume":"373","author":"Blake","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0930","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1006\/gyno.1996.0227","article-title":"A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study","volume":"62","author":"Ball","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0935","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1517\/14656560903061291","article-title":"Pharmacotherapy of endometrial cancer","volume":"10","author":"Barrena Medel","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0940","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1006\/gyno.1994.1307","article-title":"Prognostic indicators of survival in advanced endometrial cancer","volume":"55","author":"Behbakht","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0945","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/jnci\/djn397","article-title":"Systematic pelvic lymphadenectomy versus no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial","volume":"100","author":"Benedetti Panici","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0950","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/00016348009154633","article-title":"Do estrogen and progesterone receptors (E2R and PR) in metastasizing endometrial cancer predict the response to gestagen therapy?","volume":"59","author":"Benraad","year":"1980","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0955","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/01.AOG.0000149151.74863.c4","article-title":"Surgical staging for patients presenting with grade 1 endometrial carcinoma","volume":"105","author":"Ben-Shachar","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0960","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1006\/gyno.1996.0070","article-title":"Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide","volume":"60","author":"Chambers","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0965","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/cncr.22185","article-title":"Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients","volume":"107","author":"Chan","year":"2006","journal-title":"Cancer"},{"issue":"5 Pt 1","key":"10.1016\/B978-0-323-77684-4.00014-3_bib0970","first-page":"707","article-title":"Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women","volume":"97","author":"Chan","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0975","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/1097-0142(19900501)63:9<1843::AID-CNCR2820630931>3.0.CO;2-F","article-title":"Operative treatment in stage I endometrial carcinoma with deep myometrial invasion and\/or grade 3 tumor surgically limited to the corpus uteri: no recurrence with only primary surgery","volume":"63","author":"Chen","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0980","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/gyno.1997.4838","article-title":"The role of surgical cytoreduction in stage IV endometrial carcinoma","volume":"67","author":"Chi","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0985","first-page":"22","article-title":"Laparoscopic lymph node sampling","volume":"1","author":"Childers","year":"1996","journal-title":"Oper Tech Gynecol Surg"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0990","first-page":"19","article-title":"Acute morbidity and mortality associated with selective pelvic and para-aortic lymphadenectomy in the surgical staging of endometrial adenocarcinoma","volume":"1","author":"Cliby","year":"1995","journal-title":"J Gynecol Tech"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib0995","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1525-1438.1998.09865.x","article-title":"Adjuvant medroxyprogesterone acetate in high risk endometrial cancer","volume":"8","year":"1998","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1000","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1046\/j.1525-1438.1996.06020102.x","article-title":"Pelvic lymphadenectomy in high-risk endometrial cancer","volume":"6","year":"1996","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1005","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1200\/JCO.2005.04.144","article-title":"Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer","volume":"23","author":"Cragun","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1010","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/B978-0-323-77684-4.00014-3_bib1015","doi-asserted-by":"crossref","first-page":"e631","DOI":"10.1016\/j.ijrobp.2011.04.013","article-title":"Fifteen-year radiotherapy outcomes of the Randomized PORTEC-1 Trial for Endometrial Carcinoma","volume":"81","author":"Creutzberg","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1020","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.2004.08.159","article-title":"Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the postoperative radiation therapy in endometrial carcinoma trial","volume":"22","author":"Creutzberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1025","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1525-1438.2007.00897.x","article-title":"Hormone therapy in advanced and recurrent endometrial cancer: a systematic review","volume":"17","author":"DeCruze","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1030","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1200\/JCO.2008.20.6995","article-title":"Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic Oncology group trial 129P","volume":"27","author":"Dizon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1035","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0002-9378(15)33275-0","article-title":"Cytoplasmic progesterone and estriol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications","volume":"141","author":"Ehrlich","year":"1981","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1525-1438.1994.04020084.x","article-title":"The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer","volume":"4","author":"Elliott","year":"1994","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1045","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1525-1438.1998.09833.x","article-title":"Prospective evaluation of the morbidity of complete lymphadenectomy in endometrial cancer","volume":"8","author":"Fanning","year":"1998","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1050","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00006250-199102000-00024","article-title":"Serial CA125 levels during chemotherapy for metastatic or recurrent endometrial cancer","volume":"77","author":"Fanning","year":"1991","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2003.11.008","article-title":"Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Fiorica","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1060","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2004.07.184","article-title":"Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"22","author":"Fleming","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1065","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/annonc\/mdh316","article-title":"Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study","volume":"15","author":"Fleming","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ygyno.2006.02.007","article-title":"Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin\/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer","volume":"103","author":"Greven","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1075","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.ejca.2010.06.002","article-title":"Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer\u2014results from two randomised studies","volume":"46","author":"Hogberg","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1080","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ygyno.2008.11.014","article-title":"A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study","volume":"112","author":"Homesley","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1085","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1525-1438.2007.00858.x","article-title":"Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience","volume":"17","author":"Huh","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1090","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3109\/00016348409156700","article-title":"Progestin therapy of endometrial, breast, and ovarian carcinoma","volume":"63","author":"Kauppila","year":"1984","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1095","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1006\/gyno.1995.1005","article-title":"Adenocarcinoma of the endometrium: survival comparison of patients with and without pelvic node sampling","volume":"56","author":"Kilgore","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1105","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/j.1879-3479.1970.tb00172.x","article-title":"The effects of progesteronal agents on hyperplasia and carcinoma in situ of the endometrium","volume":"8","author":"Kistner","year":"1970","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1110","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(08)61766-3","article-title":"Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study","volume":"373","author":"Kitchener","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/B978-0-323-77684-4.00014-3_bib1115","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.prro.2014.01.003","article-title":"The role of postoperative radiation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence-based guideline","volume":"4","author":"Klopp","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1120","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/0090-8258(76)90050-0","article-title":"Gestagens and endometrial carcinoma","volume":"4","author":"Kohorn","year":"1976","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1125","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/jnci\/djs374","article-title":"Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis","volume":"104","author":"Kong","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1130","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1200\/JCO.2009.22.3529","article-title":"Quality of life of patients with endometrial cancer undergoing laparoscopic International Federation of Gynecology and Obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study","volume":"27","author":"Kornblith","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1135","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0029-7844(97)00698-4","article-title":"Surgery without radiotherapy for primary treatment of endometrial cancer","volume":"91","author":"Larson","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1140","first-page":"998","article-title":"Pelvic and para-aortic lymphadenectomy for surgical staging of endometrial cancer: morbidity and mortality","volume":"79","author":"Larson","year":"1992","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1145","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1046\/j.1525-1438.1997.00005.x","article-title":"Total abdominal hysterectomy and bilateral salpingo-oophorectomy: a sufficient treatment for patients with low risk endometrial carcinoma","volume":"7","author":"Leijon","year":"1997","journal-title":"Int J Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1150","first-page":"100","article-title":"Advanced and recurrent endometrial carcinoma: hormonal therapy","volume":"21","author":"Lentz","year":"1994","journal-title":"Semin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1155","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.1996.14.2.357","article-title":"High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"14","author":"Lentz","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1160","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/0090-8258(74)90028-6","article-title":"Adjuvant progestogen therapy in primary definitive treatment of endometrial cancer","volume":"2","author":"Lewis","year":"1974","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_bib1165","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2007.03.024","article-title":"External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer","volume":"106","author":"Lin","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1170","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0090-8258(02)00068-9","article-title":"Activity of paclitaxel as a second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study","volume":"88","author":"Lincoln","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"2 Pt 1","key":"10.1016\/B978-0-323-77684-4.00014-3_bib1175","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/AOG.0b013e3181af2a74","article-title":"A multiinstitutional experience with robotic-assisted hysterectomy with staging for endometrial cancer","volume":"114","author":"Lowe","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1180","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1471-0528.1988.tb06847.x","article-title":"A randomized trial of progestogens in the primary treatment of endometrial carcinoma","volume":"95","author":"Macdonald","year":"1988","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1185","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6603279","article-title":"Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial carcinoma: results of a randomized trial","volume":"95","author":"Maggi","year":"2006","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/B978-0-323-77684-4.00014-3_bib1190","first-page":"CD001040","article-title":"Progestagens for endometrial cancer","author":"Martin-Hirsch","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1195","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0002-9378(96)70679-8","article-title":"Vaginal hysterectomy versus abdominal hysterectomy for the treatment of stage I endometrial adenocarcinoma","volume":"174","author":"Massi","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1200","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ygyno.2014.07.078","volume":"134","author":"McMeekin","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1205","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2007.04.032","article-title":"The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study","volume":"106","author":"McMeekin","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"33","key":"10.1016\/B978-0-323-77684-4.00014-3_bib1210","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: Final overall survival and adverse event analysis of a phase III trial (NRG Oncology\/GOG0209)","volume":"20;38","author":"Miller","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/B978-0-323-77684-4.00014-3_bib1215","doi-asserted-by":"crossref","first-page":"535","DOI":"10.6004\/jnccn.2009.0036","article-title":"Chemo- and radiotherapy in adjuvant management of optimally debulked endometrial cancer","volume":"7","author":"Miller","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1220","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/gyno.1998.5098","article-title":"Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma","volume":"70","author":"Mohan","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1225","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1006\/gyno.1996.0040","article-title":"Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration","volume":"60","author":"Morris","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1230","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1235","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2008.20.2424","article-title":"Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial","volume":"27","author":"Nout","year":"2009","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/B978-0-323-77684-4.00014-3_bib1240","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2013.48.8023","article-title":"Long-term outcomes after pelvic radiation for early-stage endometrial cancer","volume":"31","author":"Onsrud","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1245","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0090-8258(91)90347-8","article-title":"Surgical staging of uterine cancer: an analysis of perioperative morbidity","volume":"42","author":"Orr","year":"1991","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1250","first-page":"79","article-title":"FIGO annual report, years 1996\u20131998","year":"2003","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1255","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1006\/gyno.1998.5150","article-title":"Staging and therapeutic value of lymphadenectomy in endometrial cancer","volume":"70","author":"Podratz","year":"1998","journal-title":"Gynecol Oncol"},{"issue":"16","key":"10.1016\/B978-0-323-77684-4.00014-3_bib1260","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1200\/JCO.2009.26.8326","article-title":"A phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group (GOG) study","volume":"28","author":"Powell","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/B978-0-323-77684-4.00014-3_bib1265","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III trial: Adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in high-intermediate and high-risk early stage endometrial cancer","volume":"20;37","author":"Randall","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1270","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.2004.00.7617","article-title":"Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"24","author":"Randall","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1275","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ijrobp.2005.03.007","article-title":"Postoperative radiotherapy for stage I endometrial carcinoma: long-term outcome of the randomized Portec Trial with central pathology review","volume":"63","author":"Scholten","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1280","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1046\/j.1525-1438.1998.09892.x","article-title":"Doxorubicin and\/or cisplatin based chemotherapy for the treatment of endometrial carcinoma with retroperitoneal lymph node metastases","volume":"8","author":"Selman","year":"1998","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1285","first-page":"88","article-title":"Adriamycin and cyclophosphamide chemotherapy for disseminated endometrial cancer","volume":"58","author":"Seski","year":"1981","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1290","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.ijrobp.2011.04.014","article-title":"External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma\u2014a prospective randomized study","volume":"82","author":"Sorbe","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1295","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/IGC.0b013e3181a6c9df","article-title":"Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study","volume":"19","author":"Sorbe","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1300","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1006\/gyno.2001.6494","article-title":"Conservative management of stage I endometrial carcinoma after surgical staging","volume":"84","author":"Straughn","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1305","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0090-8258(03)00087-8","article-title":"Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy","volume":"89","author":"Straughn","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1310","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2007.09.029","article-title":"Randomized phase III trial of pelvic radiotherapy vs. cisplatin-based combined chemotherapy in patients with intermediate and high-risk risk endometrial carcinoma: a Japanese Gynecologic Oncology Group study","volume":"108","author":"Susumu","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1315","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ygyno.2005.08.037","article-title":"Adjuvant whole abdominal irradiation in clinical stage I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group","volume":"100","author":"Sutton","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1320","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/0090-8258(89)90605-7","article-title":"Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"33","author":"Thigpen","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1325","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00000421-198406000-00010","article-title":"A Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study","volume":"3","author":"Thigpen","year":"1984","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1330","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1200\/JCO.1994.12.7.1408","article-title":"A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"12","author":"Thigpen","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1335","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.1999.17.6.1736","article-title":"Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group","volume":"17","author":"Thigpen","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1340","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1200\/JCO.2004.02.088","article-title":"Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study","volume":"22","author":"Thigpen","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1345","first-page":"21","article-title":"Phase II trial of Adriamycin in treatment of advanced or recurrent endometrial carcinoma","volume":"63","author":"Thigpen","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1350","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/ijgc-00009577-200301000-00007","article-title":"Low risk endometrial cancer: a study of pelvic lymph node metastasis","volume":"13","author":"Watanabe","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1355","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2003.09.018","article-title":"Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Whitney","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1360","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1046\/j.1525-1438.1997.00432.x","article-title":"Conservative management of endometrial carcinoma with prolonged preservation of the uterus in a young patient","volume":"7","author":"Zanetta","year":"1997","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1365","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1006\/gyno.1999.5444","article-title":"The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma","volume":"74","author":"Zanotti","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1370","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2005.04.027","article-title":"Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer","volume":"98","author":"Amant","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1375","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1006\/gyno.1997.4629","article-title":"Uterine carcinomas: incidence and trends in management and survival","volume":"65","author":"Arrastia","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1380","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/AOG.0b013e318176157c","article-title":"Uterine carcinosarcomas and grade 3 endometrioid cancers-evidence for distinct tumor behavior","volume":"112","author":"Bansal","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1385","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0360-3016(03)01561-X","article-title":"Malignant mixed m\u00fcllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome","volume":"58","author":"Callister","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1390","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1006\/gyno.1998.5251","article-title":"Uterine sarcomas: the Curie Institut experience\u2014prognostic factors and adjuvant treatments","volume":"72","author":"Chauveinc","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1395","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1006\/gyno.1997.4676","article-title":"The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma","volume":"65","author":"Chi","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1400","first-page":"692","article-title":"Computed tomography in endometrial cancer","volume":"95","author":"Connor","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1405","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8","article-title":"Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study","volume":"60","author":"Creasman","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1410","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1006\/gyno.2001.6256","article-title":"Paclitaxel in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"83","author":"Curtin","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1415","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: a review","volume":"116","author":"D\u2019Angelo","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1420","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0b013e3181161ba3","article-title":"Prognostic features of surgical stage I uterine carcinosarcoma","volume":"31","author":"Ferguson","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1425","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0090-8258(83)90014-8","article-title":"Treatment of advanced uterine sarcoma with adriamycin","volume":"16","author":"Hannigan","year":"1983","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1430","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0090-8258(83)90117-8","article-title":"Adjuvant chemotherapy in early uterine sarcoma","volume":"15","author":"Hannigan","year":"1983","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1435","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/JCO.2006.06.4907","article-title":"Phase III trial of ifosfamide with and without paclitaxel in advanced uterine carcinosarcoma: a GOG study","volume":"25","author":"Homesley","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1440","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2005.01.041","article-title":"Systemic therapy for advanced uterine sarcoma: a systematic review of the literature","volume":"97","author":"Kanjeekal","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1445","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1006\/gyno.1997.4625","article-title":"Malignant mixed mesodermal ovarian tumor treatment and prognosis: a 20 year experience","volume":"65","author":"Le","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1450","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/IGC.0b013e3181a831fb","article-title":"Patterns of failure for conservatively managed surgical stage in uterine carcinosarcoma\u2014implications for adjuvant therapy","volume":"19","author":"Leath","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1455","first-page":"75","article-title":"Prognostic factors in early stage uterine sarcoma","volume":"11","author":"Major","year":"1992","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1460","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/cncr.2820710440","article-title":"Prognostic factors in early-stage uterine sarcoma: a Gynecologic Oncology Group study","volume":"71","author":"Major","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1465","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2008.06.035","article-title":"A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma","volume":"111","author":"Makker","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1470","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0090-8258(84)90041-6","article-title":"Uterine sarcomas: a clinico-pathologic study, 1965-1981","volume":"18","author":"Marchese","year":"1984","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1475","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/1097-0142(19850415)55:8<1648::AID-CNCR2820550806>3.0.CO;2-7","article-title":"Treatment of recurrent or advanced uterine sarcoma: a randomized trial of doxorubicin versus doxorubicin and cyclophosphamide","volume":"55","author":"Muss","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1480","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ygyno.2008.05.016","article-title":"Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis","volume":"111","author":"Nemani","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1485","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.1985.3.9.1240","article-title":"A randomized clinical trial of adjuvant Adriamycin in uterine sarcoma: a Gynecologic Oncology Group study","volume":"3","author":"Omura","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1490","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/1097-0142(19830815)52:4<626::AID-CNCR2820520409>3.0.CO;2-E","article-title":"A randomized study of adriamycin with and without demethyl triazenoimidazole carboxamide in advanced uterine sarcomas","volume":"52","author":"Omura","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1495","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ejca.2008.01.019","article-title":"Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)","volume":"44","author":"Reed","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1500","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1006\/gyno.1997.4827","article-title":"Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study","volume":"67","author":"Sartori","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1505","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1097-0142(19860101)57:1<155::AID-CNCR2820570131>3.0.CO;2-C","article-title":"Patterns of recurrence in malignant mixed M\u00fcllerian tumor of the uterus","volume":"57","author":"Spanos","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1510","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/gyno.2000.6001","article-title":"A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"79","author":"Sutton","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1515","first-page":"161","article-title":"Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study","volume":"12","author":"Sutton","year":"1989","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1520","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1200\/JCO.1991.9.11.1962","article-title":"Phase II trial of cisplatin as first line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study","volume":"9","author":"Thigpen","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1525","first-page":"271","article-title":"Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study","volume":"70","author":"Thigpen","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1530","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1525-1438.1994.04010052.x","article-title":"The effect of chemotherapy on the different components of advanced carcinosarcomas (malignant mixed mesodermal tumors) of the female genital tract","volume":"4","author":"Van Rijswijk","year":"1994","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1535","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ygyno.2007.07.070","article-title":"A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma of the uterus","volume":"107","author":"Wolfson","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1540","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/gyno.1994.1011","article-title":"A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas","volume":"52","author":"Wolfson","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1545","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ssu.2980100510","article-title":"Gynecological sarcomas","volume":"10","author":"DiSaia","year":"1995","journal-title":"Semin Surg Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1550","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/modpathol.3880055","article-title":"Smooth muscle, endometrial stromal, and mixed M\u00fcllerian tumors of the uterus","volume":"13","author":"Kempson","year":"2000","journal-title":"Mod Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1555","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/ijgc-00009577-200211000-00001","article-title":"Uterine carcinosarcomas are metaplastic carcinomas","volume":"12","author":"McCluggage","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1560","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1749-6632.1959.tb44576.x","article-title":"Uterine sarcomas: histogenesis and taxonomy","volume":"75","author":"Ober","year":"1959","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1565","first-page":"5379","article-title":"Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors","volume":"57","author":"Wada","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1570","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/01.pgp.0000092134.88121.56","article-title":"Carcinosarcomas (malignant M\u00fcllerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis","volume":"22","author":"Zhe","year":"2003","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1575","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2003.12.029","article-title":"Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989\u20131999","volume":"93","author":"Brooks","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1580","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/jnci\/djh007","article-title":"Risk of malignant mixed M\u00fcllerian tumors after tamoxifen therapy for breast cancer","volume":"96","author":"Curtis","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1585","first-page":"399","article-title":"The epidemiology of sarcomas of the uterus","volume":"76","author":"Harlow","year":"1986","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1590","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/1097-0142(19861101)58:9<2003::AID-CNCR2820580908>3.0.CO;2-2","article-title":"An excess of uterine sarcomas after pelvic irradiation","volume":"58","author":"Meredith","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1595","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/cncr.11484","article-title":"Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus","volume":"98","author":"Sherman","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1600","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1006\/gyno.1998.4941","article-title":"Evidence for a common etiology for endometrial carcinomas and malignant mixed M\u00fcllerian tumors","volume":"69","author":"Zelmanowicz","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1605","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00004347-199504000-00007","article-title":"Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins","volume":"14","author":"Amada","year":"1995","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1610","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00000478-199406000-00001","article-title":"Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases","volume":"18","author":"Bell","year":"1994","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1615","first-page":"845","article-title":"Treatment of uterine leiomyosarcoma","volume":"71","author":"Berchuck","year":"1988","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1620","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1006\/gyno.1997.4889","article-title":"Leiomyosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases","volume":"68","author":"Blom","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1625","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ygyno.2014.11.011","article-title":"Import of morcellation on survival outcome of patients with unexpected uterine leiomyosarcoma","volume":"137","author":"Bogani","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1630","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/gyno.1996.0185","article-title":"Uterine leiomyosarcoma: analysis of treatment failures and survival","volume":"62","author":"Cadducci","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1635","first-page":"153","article-title":"Intravenous leiomyomatosis of the uterus","volume":"2","author":"Clement","year":"1988","journal-title":"Pathol Annu"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1640","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/01443610310001609597","article-title":"Uterine leiomyosarcoma discovered after uterine artery embolization","volume":"23","author":"D\u2019Angelo","year":"2003","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1645","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/1097-0142(19881115)62:10<2239::AID-CNCR2820621028>3.0.CO;2-Y","article-title":"Smooth muscle neoplasms of the uterus other than ordinary leiomyoma: a study of 46 cases, with emphasis on diagnostic criteria and prognostic factors","volume":"62","author":"Evans","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1650","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/gyno.1996.0185","article-title":"Uterine leiomyosarcoma: analysis of treatment failures and survival","volume":"62","author":"Gadducci","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1655","first-page":"209","article-title":"Leiomyomatous neoplasms of the lung","volume":"2","author":"Gal","year":"1989","journal-title":"Mod Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1660","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0090-8258(02)00136-1","article-title":"Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study","volume":"89","author":"Gallup","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1665","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0090-8258(03)00137-9","article-title":"Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy","volume":"89","author":"Giuntoli","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1670","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1006\/gyno.1993.1172","article-title":"Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence","volume":"50","author":"Goff","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1675","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2008.02.024","article-title":"Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1680","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2008.03.010","article-title":"Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1685","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ygyno.2008.11.027","article-title":"Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study","volume":"112","author":"Hensley","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1690","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1200\/JCO.2002.11.050","article-title":"Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial","volume":"20","author":"Hensley","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1695","first-page":"162","article-title":"Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas","volume":"76","author":"Leibsohn","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1700","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/0090-8258(92)90286-R","article-title":"Resection of pulmonary metastases from uterine sarcomas","volume":"45","author":"Levenback","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1705","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1006\/gyno.1998.5124","article-title":"Fertility-sparing surgery in uterine leiomyosarcoma","volume":"70","author":"Lissoni","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1710","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1634\/theoncologist.12-8-999","article-title":"Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future","volume":"12","author":"Maki","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1715","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/gyno.1999.5436","article-title":"Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases","volume":"74","author":"Mayerhofer","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1720","first-page":"529","article-title":"Unsuspected leiomyosarcoma: treatment with a gonadotropin-releasing hormone analogue","volume":"75","author":"Meyer","year":"1990","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1725","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2009.10.050","article-title":"Meeting Report\u2014The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas","volume":"115","author":"Mutch","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1730","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1046\/j.1525-1438.1993.03020110.x","article-title":"Leiomyosarcoma and endometrial stromal sarcoma of the uterus","volume":"3","author":"Nordal","year":"1993","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1735","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0046-8177(90)90133-P","article-title":"Mitotically active leiomyomas of the uterus","volume":"21","author":"O\u2019Connor","year":"1990","journal-title":"Hum Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1740","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/00000478-199507000-00003","article-title":"Cellular benign mesenchymal tumors of the uterus: a comparative morphologic and immunohistochemical analysis of 33 highly cellular leiomyomas and six endometrial stromal nodules, two frequently confused tumors","volume":"19","author":"Oliva","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1745","first-page":"414","article-title":"Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma","volume":"83","author":"Parker","year":"1994","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1750","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/00006250-199406000-00023","article-title":"Uterine smooth muscle tumor of uncertain malignant potential","volume":"83","author":"Peters","year":"1994","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1755","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1006\/gyno.1998.5080","article-title":"Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"70","author":"Rose","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1760","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0002-9378(12)90910-2","article-title":"Leiomyosarcomas: clinical presentation","volume":"168","author":"Schwartz","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1765","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/00006250-197110000-00019","article-title":"Leiomyosarcoma of the uterus","volume":"38","author":"Silverberg","year":"1971","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1770","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1006\/gyno.1999.5463","article-title":"Phase II Trial of paclitaxel in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"74","author":"Sutton","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1775","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1996.0220","article-title":"Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study","volume":"62","author":"Sutton","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1780","first-page":"295","article-title":"Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus","volume":"36","author":"Sutton","year":"1990","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1785","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00000421-198602000-00005","article-title":"Cisplatin as second line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus","volume":"9","author":"Thigpen","year":"1986","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1790","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1006\/gyno.1996.0289","article-title":"Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"63","author":"Thigpen","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1795","doi-asserted-by":"crossref","first-page":"595","DOI":"10.5858\/2008-132-595-SMTOTU","article-title":"Smooth muscle tumors of the uterus: a practical approach","volume":"132","author":"Toledo","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1800","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.2014.9005","article-title":"Unexpected gynecologic malignancy undergoing minimally invasive hysterectomy using morcellation","volume":"312","author":"Wright","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_bib1805","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jamaoncol.2014.206","article-title":"Use of electric power morcellation and prevalence of underlying cancer in women who undergo myomectomy","volume":"1","author":"Wright","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1810","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1200\/JCO.2008.19.8366","article-title":"Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems","volume":"27","author":"Zivanovic","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1815","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0028-2243(91)90144-A","article-title":"Low-grade stromal sarcoma: a benign appearing malignant uterine tumour: a review of current literature. Differential diagnostic problems illustrated by four cases","volume":"39","author":"Bohr","year":"1991","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1820","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00000478-199005000-00002","article-title":"Primary uterine endometrial stromal neoplasms: a clinicopathologic study of 117 cases","volume":"14","author":"Chang","year":"1990","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1825","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0002-9378(78)90445-3","article-title":"Endometrial sarcoma: lymphatic spread pattern","volume":"130","author":"DiSaia","year":"1978","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1830","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0090-8258(89)90002-4","article-title":"Endometrial stromal sarcomas: review of Mayo Clinic experience, 1945\u20131980","volume":"35","author":"DeFusio","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1835","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijgo.2008.12.009","article-title":"FIGO Staging for uterine sarcomas","volume":"104","author":"Committee","year":"2009","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1840","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1006\/gyno.1996.0314","article-title":"Endometrial stromal sarcoma: analysis of treatment failures and survival","volume":"63","author":"Gadducci","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1845","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ygyno.2007.01.031","article-title":"A multi-institutional review of outcomes of endometrial stromal sarcoma","volume":"105","author":"Leath","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1850","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/1097-0142(197904)43:4<1189::AID-CNCR2820430405>3.0.CO;2-E","article-title":"Complete remission of widely metastatic endometrial stromal sarcoma following combination chemotherapy","volume":"43","author":"Lehrner","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1855","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1006\/gyno.1995.1223","article-title":"Case report: prolonged stabilization of progressive endometrial stromal sarcoma with prolonged oral etoposide therapy","volume":"58","author":"Lin","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1860","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1046\/j.1525-1438.1997.00012.x","article-title":"Conservative management of endometrial stromal sarcoma in young women","volume":"7","author":"Lissoni","year":"1997","journal-title":"Int J Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1865","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/gyno.1996.0224","article-title":"The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma","volume":"62","author":"Nordal","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1870","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/1097-0142(196606)19:6<755::AID-CNCR2820190604>3.0.CO;2-U","article-title":"Mesenchymal tumors of the uterus. I: a clinical and pathological study of 53 endometrial stromal tumors","volume":"19","author":"Norris","year":"1966","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1875","first-page":"173","article-title":"Uterine endolymphatic stromal myosis: a collaborative study","volume":"64","author":"Piver","year":"1984","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1880","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1006\/gyno.1998.5174","article-title":"Case report: low-grade endometrial stromal sarcoma preoperative treatment with Depo-Lupron and Megace","volume":"71","author":"Scribner","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1885","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00000478-198901000-00004","article-title":"M\u00fcllerian adenosarcoma of the uterus with sarcomatous overgrowth: a clinicopathological analysis of 10 cases","volume":"13","author":"Clement","year":"1989","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1890","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0046-8177(90)90198-E","article-title":"M\u00fcllerian adenosarcoma of the uterus: a clinical pathological analysis of 100 cases with review of the literature","volume":"21","author":"Clement","year":"1990","journal-title":"Hum Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1895","first-page":"669","article-title":"Conservative management of uterine rhabdomyosarcoma","volume":"92","author":"Hammerman","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1900","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004347-199204000-00001","article-title":"Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases","volume":"11","author":"Kaku","year":"1992","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1905","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.2001.6334","article-title":"Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival","volume":"83","author":"Krivac","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_bib1910","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/1097-0142(19810715)48:2<354::AID-CNCR2820480222>3.0.CO;2-Q","article-title":"Adenofibroma and adenosarcoma of the uterus: a clinicopathologic study of 35 cases","volume":"48","author":"Zaloudek","year":"1981","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_bib1915","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2019.04.044","article-title":"Preliminary safety, efficacy, and pharmacokinetic\/pharmacodynamic characterization from GARNET, a phase I\/II clinical trial of the anti\u2013PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer","volume":"154","author":"Oaknin","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"15","key":"10.1016\/B978-0-323-77684-4.00014-3_bib1920","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized Phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): Updated overall survival analysis","volume":"1;26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/B978-0-323-77684-4.00014-3_ref1925","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.ygyno.2006.03.055","article-title":"The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center","volume":"103","author":"Abu-Rustum","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/B978-0-323-77684-4.00014-3_ref1930","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdv209","article-title":"Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?","volume":"26","author":"Apetoh","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/B978-0-323-77684-4.00014-3_ref1935","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2012.02.021","article-title":"The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes","volume":"125","author":"Barlin","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_ref1940","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijrobp.2012.03.011","article-title":"The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer","volume":"85","author":"Barney","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9945","key":"10.1016\/B978-0-323-77684-4.00014-3_ref1945","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0140-6736(14)60892-8","article-title":"Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults","volume":"384","author":"Bhaskaran","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/B978-0-323-77684-4.00014-3_ref1950","doi-asserted-by":"crossref","first-page":"e80023","DOI":"10.1371\/journal.pone.0080023","article-title":"Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations","volume":"8","author":"Birkbak","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/B978-0-323-77684-4.00014-3_ref1955","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ygyno.2019.03.254","article-title":"Sentinel node mapping vs. lymphadenectomy in endometrial cancer: a systematic review and meta-analysis","volume":"153","author":"Bogani","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"13","key":"10.1016\/B978-0-323-77684-4.00014-3_ref1960","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.ejca.2015.05.015","article-title":"Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer\u2014a pooled analysis of PORTEC 1 and 2 trials","volume":"51","author":"Bosse","year":"2015","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/B978-0-323-77684-4.00014-3_ref1965","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1200\/JCO.2005.02.7227","article-title":"Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors","volume":"24","author":"Buhard","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/B978-0-323-77684-4.00014-3_ref1970","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"issue":"Suppl 5","key":"10.1016\/B978-0-323-77684-4.00014-3_bib1975","article-title":"ENGOT-EN9\/LEAP-001: a phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced endometrial cancer","volume":"30","author":"Marth","year":"2019","journal-title":"Ann Oncol"},{"issue":"7447","key":"10.1016\/B978-0-323-77684-4.00014-3_ref1980","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/B978-0-323-77684-4.00014-3_ref1985","first-page":"240","article-title":"Postoperative neuropathies after major pelvic surgery","volume":"100","author":"Cardosi","year":"2002","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/B978-0-323-77684-4.00014-3_ref1990","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ygyno.2013.10.010","article-title":"Early stage papillary serous or clear cell carcinoma confined to or involving an endometrial polyp: outcomes with and without adjuvant therapy","volume":"131","author":"Chang-Halpenny","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_ref1995","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ygyno.2016.07.114","article-title":"Implication of genomic characterization in synchronous endometrial and ovarian cancers of endometrioid histology","volume":"143","author":"Chao","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2000","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1006\/gyno.1999.5505","article-title":"Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma","volume":"74","author":"Cirisano","year":"1999","journal-title":"Gynecol Oncol"},{"issue":"22","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2005","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.19.00151","article-title":"Hysterectomy-corrected uterine corpus cancer incidence trends and differences in relative survival reveal racial disparities and rising rates of nonendometrioid cancers","volume":"37","author":"Clarke","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2010","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/bjc.2013.59","article-title":"Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial","volume":"108","author":"Colombo","year":"2013","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2015","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ygyno.2017.03.017","article-title":"Surgical-pathological findings in type 1 and 2 endometrial cancer: an NRG Oncology\/Gynecologic Oncology Group study on GOG-210 protocol","volume":"145","author":"Creasman","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2020","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1634\/theoncologist.2018-0160","article-title":"A phase II trial of sorafenib and dacarbazine for leiomyosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumors","volume":"24","author":"D\u2019Adamo","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ygyno.2014.09.011","article-title":"Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study","volume":"136","author":"Darai","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2035","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"de Boer","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2040","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/B978-0-323-77684-4.00014-3_bib2045","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMc1510353","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"373","author":"Diaz","year":"2015","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2050","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2055","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ygyno.2012.09.026","article-title":"Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer","volume":"128","author":"Garg","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2065","first-page":"2207","article-title":"Synchronous endometrioid endometrial and ovarian carcinomas are biologically related: a clinico-pathological and molecular (next generation sequencing) study of 22 cases","volume":"17","author":"Hajkova","year":"2019","journal-title":"Oncol Lett"},{"issue":"33","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2070","doi-asserted-by":"crossref","first-page":"JCO1800454","DOI":"10.1200\/JCO.18.00454","article-title":"Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: a phase III NRG Oncology\/Gynecologic Oncology Group Study","volume":"36","author":"Hensley","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2075","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2014.58.3781","article-title":"Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology\/Gynecologic Oncology Group study","volume":"33","author":"Hensley","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2080","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/modpathol.3800271","article-title":"Minimal uterine serous carcinoma: a clinicopathological study of 40 cases","volume":"18","author":"Hui","year":"2005","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/B978-0-323-77684-4.00014-3_bib2090","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ygyno.2020.12.010","article-title":"Clinical significance of homologous recombination deficiency score testing in endometrial cancer","volume":"160","author":"Siedel","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2095","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1159\/000480237","article-title":"Is omentectomy necessary for non-endometrioid endometrial cancer","volume":"83","author":"Kaban","year":"2018","journal-title":"Gynecol Obstet Invest"},{"issue":"2","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2100","doi-asserted-by":"crossref","first-page":"170","DOI":"10.6004\/jnccn.2018.0006","article-title":"Uterine neoplasms, Version 1.2018, NCCN clinical practice guidelines in oncology","volume":"16","author":"Koh","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"30","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2105","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1200\/JCO.19.01021","article-title":"Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent\/persistent endometrial cancer","volume":"37","author":"Konstantinopoulos","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6349","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2110","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"17","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2115","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1002\/cncr.30745","article-title":"Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing","volume":"123","author":"Le Gallo","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_ref2120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41392-019-0049-6","article-title":"Pazopanib in advanced soft tissue sarcomas","volume":"4","author":"Lee","year":"2019","journal-title":"Signal Transduct Target Ther"},{"issue":"29","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2125","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/B978-0-323-77684-4.00014-3_bib2130","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMra1514010","article-title":"Endometrial cancer","volume":"383","author":"Lu","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2135","doi-asserted-by":"crossref","first-page":"588.e581","DOI":"10.1016\/j.ajog.2016.06.005","article-title":"Robotic-assisted vs traditional laparoscopic surgery for endometrial cancer: a randomized controlled trial","volume":"215","author":"M\u00e4enp\u00e4\u00e4","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2140","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2150","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2155","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2160","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2007.04.032","article-title":"The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study","volume":"106","author":"McMeekin","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"33","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2165","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/B978-0-323-77684-4.00014-3_bib2170","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.19.01240","article-title":"Beyond obesity: the rising incidence and mortality rates of uterine corpus cancer","volume":"37","author":"Mullins","year":"2019","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2175","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 Study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2180","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ygyno.2017.05.024","article-title":"Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: does adjuvant treatment matter?","volume":"146","author":"Plante","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"17","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2185","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2190","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in high-intermediate and high-risk early stage endometrial cancer","volume":"37","author":"Randall","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10189","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2195","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2200","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1470-2045(17)30068-2","article-title":"A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study","volume":"18","author":"Rossi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2205","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2005.03.041","article-title":"Determination of HER2\/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization","volume":"98","author":"Santin","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2210","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1525-1438.2001.01065.x","article-title":"Omentectomy, peritoneal biopsy and appendectomy in patients with clinical stage I endometrial carcinoma","volume":"11","author":"Saygili","year":"2001","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2215","doi-asserted-by":"crossref","first-page":"djv427","DOI":"10.1093\/jnci\/djv427","article-title":"Massively parallel sequencing-based clonality analysis of synchronous endometrioid endometrial and ovarian carcinomas","volume":"108","author":"Schultheis","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2220","doi-asserted-by":"crossref","first-page":"329.e1","DOI":"10.1016\/j.ajog.2017.11.601","article-title":"Prognosis and treatment of positive peritoneal cytology in early endometrial cancer: matched cohort analyses from the National Cancer Database","volume":"218","author":"Seagle","year":"2018","journal-title":"Am J Obstet Gynecol"},{"issue":"11","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2225","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2230","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2235","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2240","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1002\/cncr.25515","article-title":"A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma","volume":"116","author":"Slomovitz","year":"2010","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2245","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2250","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ygyno.2017.05.016","article-title":"A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer","volume":"146","author":"Soliman","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2255","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2260","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2265","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2007.11.008","article-title":"Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review","volume":"108","author":"Thomas","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2270","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/PGP.0000000000000109","article-title":"Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma","volume":"34","author":"Tolcher","year":"2015","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2275","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2012.12.026","article-title":"Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer","volume":"129","author":"Townamchai","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"Suppl 5","key":"10.1016\/B978-0-323-77684-4.00014-3_bib2280","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/annonc\/mdz250.002","article-title":"Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)","volume":"30","author":"Makker","year":"2019","journal-title":"Ann Oncol"},{"issue":"9829","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2285","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2290","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/01443610601056418","article-title":"Preoperative assessment of deep myometrial and cervical invasion in endometrial carcinoma: comparison of magnetic resonance imaging and histopathologic evaluation","volume":"27","author":"Vasconcelos","year":"2007","journal-title":"J Obstet Gynaecol"},{"issue":"Suppl 15","key":"10.1016\/B978-0-323-77684-4.00014-3_bib2295","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1200\/jco.2013.31.15_suppl.5520","article-title":"A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: angiopoietin-2 as a predictive marker for clinical outcomes","volume":"31","author":"Vergote","year":"2013","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/B978-0-323-77684-4.00014-3_ref2300","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/B978-0-323-77684-4.00014-3_bib2305","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2019.37.15_suppl.5501","article-title":"Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601)","volume":"37","author":"Antill","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2310","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1006\/gyno.2001.6400","article-title":"Simultaneously detected endometrial and ovarian carcinomas\u2014a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study","volume":"83","author":"Zaino","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2315","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1073\/pnas.1222577110","article-title":"Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma","volume":"110","author":"Zhao","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2320","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/PAS.0b013e318202772e","article-title":"A proposed model for endometrial serous carcinogenesis","volume":"35","author":"Zheng","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/B978-0-323-77684-4.00014-3_ref2325","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2010.223","article-title":"Immune parameters affecting the efficacy of chemotherapeutic regimens","volume":"8","author":"Zitvogel","year":"2011","journal-title":"Nat Rev Clin Oncol"}],"container-title":["DiSaia and Creasman Clinical Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323776844000143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323776844000143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T14:59:03Z","timestamp":1684162743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323776844000143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780323776844"],"references-count":464,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-77684-4.00014-3","relation":{},"subject":[],"published":{"date-parts":[[2023]]}}}